Study to estimate the burden of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in Italy
Trial overview
Overall incidence rate of Herpes Zoster (HZ) cases, by age and gender
Timeframe: Day 0 to 2 years
Percentage of Postherpetic Neuralgia (PHN) cases among HZ, overall
Timeframe: At Day 90, 180 and 270 after onset of HZ
General medical history of cases with HZ, overall
Timeframe: Between Day 0 and Day 270.
Other general medical history characteristics for HZ cases, overall
Timeframe: Between Day 0 and Day 270.
Clinical information of cases with HZ, overall
Timeframe: Between Day 0 and Day 270
Complications related to HZ cases, overall
Timeframe: Between Day 0 and Day 270
Other complications related to HZ cases, overall
Timeframe: Between Day 0 and Day 270
Direct medical costs, direct non-medical costs and indirect costs
Timeframe: Up to Day 90
Worst pain assessment in HZ subjects
Timeframe: At Day 90
Average pain assessment in HZ subjects
Timeframe: At Day 90
Impact of HZ on quality of life as assessed by the Zoster Pain Inventory
Timeframe: At Day 0, 15, 30, 60, 90
Impact of HZ on quality of life as assessed by the EuroQoL-Five Digits
Timeframe: At Day 0, 15, 30, 60, 90
PHN direct medical costs, direct non-medical costs and indirect costs by payer/societal perspective
Timeframe: Between Day 90 and Day 270
Worst pain assessment in PHN subjects
Timeframe: At Day 90
Average pain assessment in PHN subjects
Timeframe: At Day 90
Impact of PHN on quality of life as assessed by the Zoster Pain Inventory
Timeframe: At Day 0, 15, 30, 60, 90
Impact of PHN on quality of life as assessed by the EuroQoL-Five Digits
Timeframe: At Day 0, 15, 30, 60, 90
Participation criteria
- A male or female ≥ 50 years of age at the time of study enrolment presenting with acute HZ.
- HZ diagnosis for this HZ episode:
- Patient participating in another clinical study (participation in another observational, non-interventional trial is allowed).
- HZ diagnosis for this HZ episode:
- Is his/her first outpatient diagnosis (i.e. initial consultation), OR
- Written informed consent obtained from the patient.
- Ability to comply with study procedures.
A male or female ≥ 50 years of age at the time of study enrolment presenting with acute HZ.
Took place at another site/centre (e.g. emergency room or Dermatologist/Specialist practice) provided the HZ diagnosis is not more than 7 days before the initial visit for the present study (i.e. secondary consultation).
Patient participating in another clinical study (participation in another observational, non-interventional trial is allowed).
Trial location(s)
Study documents
If you wish to request for full study report, please contact - [email protected]
Results overview
No study documents available
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.